EMA and the pharmaceutical industry By Anna Jurczynska | August 3, 2017 Posted in Recent News and tagged Annual Report of EMA interactions with industry stakeholders, Eligibility criteria, ema, European Commission EU Transparency registry, European Medicines Agency, Framework for interaction, survey ← Concept paper on development and lifecycle of personalised medicines and companion diagnosticsFDA Tackles Drug Competition to Improve Patient Access →
